AveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16

CHICAGO, March 08, 2016 -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, March 16, 2016 after the close of U.S.-based financial markets. AveXis management will host a conference call and live webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern Standard Time.

Analysts and investors can participate in the conference call by dialing (877) 508-0547 for domestic callers and (281) 973-6085 for international callers, using the conference ID 62607679. The webcast can be accessed live on the Events and Presentations page in the Investors and Media section of the AveXis website, www.AveXis.com. The webcast will be archived on the company’s website until its next earnings call, and will be available for telephonic replay for 14 days following the call by dialing (855) 859-2056 (Domestic) or (404) 537-3406 (International), conference ID 62607679.

About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.

Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
[email protected]

Investor Inquiries: 
Jim Goff
AveXis, Inc.
650-862-4134
[email protected]